<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725188</url>
  </required_header>
  <id_info>
    <org_study_id>7684A-002</org_study_id>
    <secondary_id>MK-7684A-002</secondary_id>
    <secondary_id>2020-004034-38</secondary_id>
    <nct_id>NCT04725188</nct_id>
  </id_info>
  <brief_title>Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare pembrolizumab/vibostolimab coformulation&#xD;
      (MK-7684A) plus docetaxel or pembrolizumab/vibostolimab coformulation to normal saline&#xD;
      placebo plus docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and&#xD;
      progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior&#xD;
      anti- programmed cell death 1 (PD-1)/ programmed cell death ligand 1(PD-L1) monoclonal&#xD;
      antibody (mAb). MK-7684A is a coformulation product of pembrolizumab/vibostolimab. The dual&#xD;
      primary hypotheses of the study are pembrolizumab/vibostolimab coformulation plus docetaxel&#xD;
      and pembrolizumab/vibostolimab coformulation is superior to normal saline placebo plus&#xD;
      docetaxel with respect to progression free survival (PFS) per Response Evaluation Criteria in&#xD;
      Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants may receive additional 17 cycles of pembrolizumab/vibostolimab (each cycle&#xD;
      length = 21 days) for an additional 1 year of treatment as second course phase at&#xD;
      investigator's discretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">August 13, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Arm 1 and Arm 3: Double-blind with in-house blinding Arm 2: Unblinded Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment</measure>
    <time_frame>Up to approximately 27 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR) per RECIST 1.1 by BICR Assessment</measure>
    <time_frame>Up to approximately 27 months</time_frame>
    <description>OR is defined as a confirmed complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 77 months</time_frame>
    <description>OS is defined as the time from randomization to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST 1.1 by BICR Assessment</measure>
    <time_frame>Up to approximately 77 months</time_frame>
    <description>For participants who demonstrate a confirmed CR (Disappearance of all target lesions) or confirmed PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 77 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Number of participants who experience an AE will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 37 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Number of participants who discontinue study treatment due to an AE will be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Metastatic Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m^2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Pembrolizumab/Vibostolimab coformulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Placebo + Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive normal saline IV infusion, Q3W for up to 35 cycles up to approximately 2 years plus Docetaxel 75 mg/m^2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab/Vibostolimab coformuation</intervention_name>
    <description>Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.</description>
    <arm_group_label>Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel</arm_group_label>
    <arm_group_label>Arm 2: Pembrolizumab/Vibostolimab coformulation</arm_group_label>
    <other_name>MK-7684A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.</description>
    <arm_group_label>Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel</arm_group_label>
    <arm_group_label>Arm 3: Placebo + Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline IV infusion Q3W up to approximately 2 years</description>
    <arm_group_label>Arm 3: Placebo + Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell&#xD;
             lung cancer (NSCLC)&#xD;
&#xD;
          -  Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma&#xD;
             kinase (ALK), or reactive oxygen species (ROS) 1 directed therapy is not indicated as&#xD;
             primary therapy&#xD;
&#xD;
          -  Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1&#xD;
             (PD-1)/ programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered&#xD;
             either as monotherapy or in combination with other checkpoint inhibitors or other&#xD;
             therapies&#xD;
&#xD;
               -  Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall&#xD;
                  course of treatment&#xD;
&#xD;
          -  Has PD as determined by the investigator after platinum doublet chemotherapy for&#xD;
             metastatic disease&#xD;
&#xD;
          -  Has measurable disease defined as at least 1 measurable lesion by computed tomography&#xD;
             (CT) or magnetic resonance imaging (MRI), based on Response Evaluation Criteria in&#xD;
             Solid Tumors Version 1.1 (RECIST 1.1)&#xD;
&#xD;
          -  Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample or&#xD;
             newly obtained core or excisional biopsy of a tumor lesion not previously irradiated&#xD;
&#xD;
          -  Has a life expectancy of at least 3 months&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed&#xD;
             within 7 days prior to randomization&#xD;
&#xD;
          -  Male participants randomized to docetaxel are eligible to participant if they agree to&#xD;
             refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse;&#xD;
             or 2) must agree to follow contraceptive guidance as per study protocol unless&#xD;
             confirmed to be azoospermic during the intervention period and for at least 180 days&#xD;
             after the last dose of docetaxel&#xD;
&#xD;
          -  Female participants must be not pregnant, not breastfeeding, and not be a woman of&#xD;
             child-bearing potential (WOCBP). A WOCBP is eligible is she agrees to either use&#xD;
             contraception, or be abstinent from heterosexual intercourse during the intervention&#xD;
             period and for ≥120 days after the last dose of study intervention. If a WOCBP is&#xD;
             randomized to docetaxel, she agrees not to donate eggs and either uses contraception&#xD;
             or be abstinent from heterosexual intercourse during the treatment period and for ≥180&#xD;
             days after the last dose of docetaxel&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has known active or untreated central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis&#xD;
&#xD;
          -  Has a known history of an additional malignancy, except if the participant has&#xD;
             undergone potentially curative therapy with no evidence of that disease recurrence for&#xD;
             at least 3 years since initiation of that therapy&#xD;
&#xD;
          -  Has received docetaxel as monotherapy or in combination with other therapies&#xD;
&#xD;
          -  Has received previous treatment with another agent targeting the T-cell immunoreceptor&#xD;
             with immunoglobulin [Ig] and immunoreceptor tyrosine-based inhibitory motif [ITIM]&#xD;
             domains (TIGIT) pathway&#xD;
&#xD;
          -  Has received radiotherapy within 2 weeks of start of study intervention. One week&#xD;
             washout is permitted for palliative radiation to non-CNS disease&#xD;
&#xD;
          -  Has received a live or live-attenuated vaccine within 30 days before the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks before the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Has severe hypersensitivity (≥Grade 3) to docetaxel or pembrolizumab/vibostolimab&#xD;
             coformulation and/or any of its excipients Has an active autoimmune disease that has&#xD;
             required systemic treatment in past 2 years&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days before the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Has interstitial lung disease, or history of pneumonitis requiring steroids for&#xD;
             treatment&#xD;
&#xD;
          -  Has known history of active human immunodeficiency virus (HIV), Hepatitis B or&#xD;
             Hepatitis C&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
&#xD;
          -  Has a known psychiatric or substance abuse disorder that would interfere with the&#xD;
             participant's ability to cooperate with the requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Illinois Cancer Care ( Site 2534)</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington-Research ( Site 2502)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>859-260-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic Hematology/Oncology ( Site 2511)</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>601-261-1700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Research - David C. Pratt Cancer Center ( Site 2532)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Research - Cancer and Hematology Center ( Site 2535)</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore- Einstein Center for Cancer Care-Oncology ( Site 2509)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 2526)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Francis Cancer Center-Research Office ( Site 2531)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>000-000-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Oncología e Investigación de Buenos Aires ( Site 0008)</name>
      <address>
        <city>Berazategui</city>
        <state>Buenos Aires</state>
        <zip>B1884BBF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54114256-2451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de Comunidad ( Site 0004)</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>005492235399323</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clínicas Mar del Plata ( Site 0002)</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>005492235937663</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncología de Rosario ( Site 0003)</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543414218909</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Universitario de Córdoba ( Site 0001)</name>
      <address>
        <city>Cordoba</city>
        <zip>5016</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543514688800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0005)</name>
      <address>
        <city>La Rioja</city>
        <zip>F5300COE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54 03804436443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital ( Site 0104)</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+610251242220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital-Clinical Trials Service ( Site 0106)</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>611300744284</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital-Medical Oncology ( Site 0102)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61861526530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0203)</name>
      <address>
        <city>Linz</city>
        <state>Oberosterreich</state>
        <zip>4040</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>004373276764226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz ( Site 0201)</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>004331638512183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0204)</name>
      <address>
        <city>Wien</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00431277002208</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0333)</name>
      <address>
        <city>Mechelen</city>
        <state>Antwerpen</state>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3215892040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel ( Site 0336)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3224775457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi-Oncology &amp; Hematology ( Site 0337)</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3271104701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis-Pulmonology &amp; Thoracic Oncology ( Site 0338)</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+32472565987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas ( Site 0334)</name>
      <address>
        <city>Sint-Niklaas</city>
        <state>Oost-Vlaanderen</state>
        <zip>1932</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3237602327</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 0700)</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>004524998173</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopistollinen sairaala-Oncology ( Site 0906)</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358331163254</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaasan Keskussairaala ( Site 0903)</name>
      <address>
        <city>Vaasa</city>
        <state>Pohjanmaa</state>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358062136981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulun yliopistollinen sairaala ( Site 0902)</name>
      <address>
        <city>Oulu</city>
        <state>Pohjois-Pohjanmaa</state>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35883153789</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital-The Department of Pulmonary Medicine ( Site 0905)</name>
      <address>
        <city>Turku</city>
        <state>Varsinais-Suomi</state>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358503442175</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil (NHC) ( Site 1000)</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33 (0)3 69 55 09 05</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre ( Site 1006)</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33231064676</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1009)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33556333333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 1008)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33 5 61 77 22 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Ambroise Paré ( Site 1007)</name>
      <address>
        <city>Beuvry</city>
        <state>Pas-de-Calais</state>
        <zip>62660</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33321619270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Sainte Anne ( Site 1003)</name>
      <address>
        <city>Toulon</city>
        <state>Var</state>
        <zip>83800 Cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33 483162503</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1004)</name>
      <address>
        <city>Avignon</city>
        <state>Vaucluse</state>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33432759330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologie Ravensburg ( Site 1104)</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Wurttemberg</state>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+497513661970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center ( Site 1202)</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+ 97286400795</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus-Oncology ( Site 1203)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>972-4-7776412</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center-Oncology ( Site 1206)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9013102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972587040620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 1205)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972 36973494</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1303)</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390630156318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1308)</name>
      <address>
        <city>Naples</city>
        <state>Napoli</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>390817062869</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRO-IRCCS-medical oncology ( Site 1304)</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>390434659127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera S Luigi Gonzaga-Oncologia Polmonare ( Site 1300)</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0119026334</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1306)</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0557947298</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele-Oncologia Medica ( Site 1305)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>390226436627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1301)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>390257489440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital-Internal medicine ( Site 2004)</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungbuk</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82432696015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 2003)</name>
      <address>
        <city>Seongnam</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877071</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2005)</name>
      <address>
        <city>Suwon-si</city>
        <state>Kyonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82312498153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center-Oncology ( Site 2000)</name>
      <address>
        <city>Songpagu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre ( Site 1501)</name>
      <address>
        <city>Lembah Pantai</city>
        <state>Kuala Lumpur</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60378414000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Tengku Ampuan Afzan ( Site 1500)</name>
      <address>
        <city>Kuantan</city>
        <state>Pahang</state>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6095139378</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225463066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska KOMED ( Site 1704)</name>
      <address>
        <city>Konin</city>
        <state>Wielkopolskie</state>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48632428009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast</state>
        <zip>190020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>79111005005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 1911)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast</state>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79111019156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical-Oncology department ( Site 1912)</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaya Oblast</state>
        <zip>121205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79150211451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Research Center-Chemotherapy department ( Site 1910)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74953043039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the Presidential Administrative Department ( Site 1902)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955300111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 1909)</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79107959868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary ( Site 1908)</name>
      <address>
        <city>Omsk</city>
        <state>Omskaya Oblast</state>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>79618813141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219437168</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>GBUZ LOKB-Oncology department #1 ( Site 1905)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219075211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932275402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau-Oncología Médica ( Site 2102)</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34935565651</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2101)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915868115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 2103)</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955015273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Bellinzona e Valli ( Site 2203)</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>041918118045</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital at Kaohsiung ( Site 2303)</name>
      <address>
        <city>Kaohsiung Niao Sung Dist</city>
        <state>Kaohsiung</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88677317123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital-Chest ( Site 2307)</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886-4-2359-2525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 2302)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital-Chest Medicine ( Site 2305)</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886225433535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University ( Site 2403)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6622516704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital ( Site 2400)</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6624194488</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death Receptor 1 (PD-1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 1 (PD-L1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 2 (PD-L2)</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>PD-L2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

